SCHEMBL3501701

SCHEMBL3501701

CCOC(=O)CCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.59
PAM P19021 2/20 0.59
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 7/20 0.56
PPARD Q03181 7/20 0.56
PPARA Q07869 7/20 0.56
TSHR P16473 6/20 0.56
HDAC11 Q96DB2 5/20 0.56
PTPN1 P18031 3/20 0.56
ALDH1A1 P00352 3/20 0.56
TDP1 Q9NUW8 3/20 0.56
TLR2 O60603 2/20 0.56
FABP4 P15090 2/20 0.56
ALOX15 P16050 2/20 0.56
HSD17B10 Q99714 2/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
MEN1 O00255 1/20 0.56
ESR1 P03372 1/20 0.56
PDE4A P27815 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL896704 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL10722961 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL3502582 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL9444562 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL15798147 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL3505405 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL14810027 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL1231751 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL3505255 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD
SCHEMBL1115129 1.00 CYP1A2 (0.59) CYP1A2PAMGPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462375-A Synthesis method and application of long-chain alkane diacid mono-tert-butyl ester 四川普康药业有限公司 2025-02-18 CN disclosed
CN-118772389-A Bio-based polyester containing aliphatic long-chain dibasic acid structure and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2024-10-15 CN disclosed
EP-3992288-A1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME BioNTech Delivery Technologies GmbH (DE) 2022-05-04 EP disclosed
EP-3500673-B1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME BIONTECH DELIVERY TECH GMBH (DE) 2021-10-06 EP disclosed
US-10894962-B2 Carboxylated 2′-amino-LNA nucleotides and oligonucleotides comprising the same BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2021-01-19 US disclosed
US-20190203208-A1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2019-07-04 US disclosed
EP-3500673-A1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME Panzner, Steffen (DE) 2019-06-26 EP disclosed
WO-2018033492-A1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME PANZNER STEFFEN (DE) 2018-02-22 WO disclosed
US-9458219-B2 Human insulin analogue and acylated derivative thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2016-10-04 US disclosed
US-20150191607-A1 Anti-fouling Paints and Coatings REACTIVE SURFACES, LTD (US) 2015-07-09 US disclosed
US-20140329745-A1 HUMAN INSULIN ANALOGUE AND ACYLATED DERIVATIVE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2014-11-06 US disclosed
WO-2013042797-A1 PROCESS FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-28 WO disclosed
US-20100210745-A1 Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes REACTIVE SURFACES, LTD. (US) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329745-A1 HUMAN INSULIN ANALOGUE AND ACYLATED DERIVATIVE THEREOF IAPP, INSR, INSRR CYP1A2 2432/4885PAM 429/4885GPR84 1877/4885
US-20190203208-A1 CARBOXYLATED 2'-AMINO-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES COMPRISING THE SAME DCTD, NSUN2, SLC29A2 CYP1A2 4659/4885PAM 588/4885GPR84 1097/4885
US-10894962-B2 Carboxylated 2′-amino-LNA nucleotides and oligonucleotides comprising the same DCTD, NSUN2, TRDMT1 CYP1A2 4708/4885PAM 617/4885GPR84 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.